Introduction {#s1}
============

Alzheimer\'s disease (AD) is a chronic neurodegenerative disease that usually affects people older than 60 years. The etiologies of many neurodegenerative diseases are not limited to a single gene or pathway, but are rather an intricate network of causatives, including neuroinflammation, oxidative stress, mitochondrial dysfunction, protein misfolding, and aggregation that can lead to cell death ([@B178]; [@B81]). Various mechanisms were associated with the sporadic form of AD, which accounts for most AD cases, whereas mutations of three genes, including amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) are heavily linked with familial AD cases ([@B119]). The irreversible symptoms of AD, such as progressive deterioration of intellect, memory, and attentiveness, are noticeable when both NFTs and Aβ plaques have disseminated through the limbic system ([@B22]).

Aβ plaques-induced brain atrophy begins with the loss of synapses and enlargement of the ventricles ([@B135]), whereas NFTs are often associated with grey matter loss ([@B8]). Progressive loss of cortical interneurons and specific neurotransmitter pathways such as acetylcholine (ACh), noradrenaline (NA), and serotonin (5-HT) are also reported in AD ([@B139]). In the early stages of AD, typically around age 70, cells in the hippocampus start to degenerate, causing mild forgetfulness of recent events and familiar names, and also difficulty in solving simple mathematical problems ([@B146]; [@B10]). After 10 years, atrophy of the cerebral cortex occurs in moderate AD stage, resulting in a decline in language, emotional outbursts, impaired ability in conducting simple tasks such as combing hair and buttoning shirts, and an inability to think clearly. In advanced stages of AD, where more nerve cells have undergone degeneration, patients are often agitated, wandering, and unable to recognize faces and communicate ([@B17]).

AD-related deaths have markedly increased over the past two decades, but a cure remains elusive ([@B4]). Treatment options for AD that are approved by the Food and Drug Administration (FDA) do not have a curative effect or are able to slow down the progression of the disease ([@B53]). The most commonly prescribed drugs are acetylcholinesterase inhibitors (AChEIs), such as tacrine, donepezil, rivastigmine, and galantamine, and N-methyl-D-aspartate receptor (NMDAr) antagonists, such as memantine ([@B114]; [**Table 1**](#T1){ref-type="table"}). Tacrine was eventually discontinued due to its hepatotoxicity, and tacrine hybrids are now being studied ([@B142]). AChEIs delay the metabolism of ACh by inhibiting acetylcholinesterase (AChE) as AD patients have a deficiency of ACh ([@B90]). Meanwhile, memantine prevents excitotoxicity by blocking NMDAr\'s activation ([@B109]).

###### 

Conventional available pharmacotherapy for Alzheimer\'s disease.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug Name      Mechanism                                  Dosage                                                                                                                                                                                                       References
  -------------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------
  Tacrine        AChE inhibitor                             Oral q.i.d.: 10 -- 20 mg (halted due to its hepatotoxicity)                                                                                                                                                  ([@B142])\
                                                                                                                                                                                                                                                                         ([@B102])

  Donepezil      AChE inhibitor                             Mild-to-moderate AD: Tablet q.d.: 5 mg, 10 mgOrally disintegrating tablet q,d,: 5 mg, 10 mgModerate-to-severe AD: Tablet q.d.: 10 mg,Orally disintegrating tablet q,d,: 10 mgSevere AD: Tablet q.d.: 23 mg   ([@B110])\
                                                                                                                                                                                                                                                                         ([@B55])\
                                                                                                                                                                                                                                                                         ([@B180])\
                                                                                                                                                                                                                                                                         ([@B13])\
                                                                                                                                                                                                                                                                         ([@B95])

  Rivastigmine   AChE inhibitor                             Mild-to-moderate AD: Capsule b.i.d.: 1.5 mg, 3 mg, 4.5 mg, 6 mgPatch q.d.: 4.6 mg, 9.5 mgSevere AD: Patch q.d.: 13.3 mg                                                                                      ([@B12])\
                                                                                                                                                                                                                                                                         ([@B26])

  Galantamine    AChE inhibitor                             Mild-to-moderate AD: Tablet b.i.d.: 4 mg, 8 mg, 12 mgSolution b.i.d.: 4 mgExtended-release capsule q.d.: 8 mg, 16 mg, 24 mg                                                                                  ([@B168])\
                                                                                                                                                                                                                                                                         ([@B118])\
                                                                                                                                                                                                                                                                         ([@B124])\
                                                                                                                                                                                                                                                                         ([@B14])\
                                                                                                                                                                                                                                                                         ([@B125])

  Memantine      N-methyl-D-aspartate receptor antagonist   Moderate-to-severe AD: Tablet b.i.d.: 5 mg, 10 mgSolution b.i.d.: 2 mg/mlExtended-release capsule q.d.: 7 mg, 14 mg, 21 mg, 28 mg                                                                            ([@B177])\
                                                                                                                                                                                                                                                                         ([@B144])\
                                                                                                                                                                                                                                                                         ([@B36])\
                                                                                                                                                                                                                                                                         ([@B54])\
                                                                                                                                                                                                                                                                         ([@B87])\
                                                                                                                                                                                                                                                                         ([@B82])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

q.i.d., four times a day; q.d., once a day; b.i.d., twice a day.

Heterogeneity in AD pathogenesis impedes the development of curative strategies. Three neuropathological mechanisms postulated in AD are: i) formation of extracellular Aβ plaques by insoluble amyloid proteins\' aggregate, ii) formation of NFTs (disorganized bundles of filaments in the neuronal cytoplasm) by hyperphosphorylated tau proteins, and iii) neuronal loss as the aftermath of the Aβ plaques and NFTs ([@B138]). Thus, many drugs failed to improve cognition in mild-to-moderate AD patients as the drugs target a single pathology without acknowledging other neurological insults ([@B79]). Hence, a multi-target approach is being highly investigated in clinical trials to synergistically target distinct pathways and ameliorate AD ([@B34]).

Amyloid Plaques {#s2}
===============

Overproduction and reduced clearance of Aβ~42~ monomers cause the deposition of Aβ plaques that eventually leads to alteration in downstream neurobiological events ([@B158]). Aβ plaques cause catastrophic damage to cellular membranes\' integrity through the formation of the membrane\'s pore and the reduction of the membrane\'s fluidity, hence, leading to neuronal death ([@B179]). Aβ plaques also trigger the activation of microglia and astrocyte as an inflammatory response, alter the neuronal calcium homeostasis causing oxidative injury, and disrupt the protein kinase and phosphatase-related pathways, resulting in hyperphosphorylation of tau and formation of NFTs ([@B136]). Furthermore, self-propagation of Aβ~42~ plaques and hyperphosphorylated tau, *via* a prion-like mechanism, may exaggerate the synaptic dysfunction, neurotransmitter deficits, and neuronal loss in the brain ([@B62]).

Although Aβ plaques alone may not be adequate in causing the transmission of pathological tau, amyloid cascade hypothesis suggests that deposition Aβ plaques is the triggering factor for the cognitive deteriorations in AD ([@B15]). Hence, future drug development should seek to determine whether a single-target therapy targeting Aβ is sufficient to treat AD or whether a combination therapy between anti-Aβ and anti-tau is needed ([@B68]).

Neurofibrillary Tangles {#s3}
=======================

Intracellular NFTs are the deposits of insoluble proteins in neuronal cell bodies ([@B165]). Tau is a cytoskeletal microtubule-associated protein (MAP) that is phosphorylated at three sites - serine (S), threonine (T), and at residues adjacent to proline - and binds at the microtubules (MTs) to sustain the MTs\' stability and integrity ([@B134]). The toxicity of tau can impair neuronal function depending on its post-translational modifications. The most potent phosphorylations of tau take place at T231, S235, and S262, which results in the loss of tau\'s ability to bind to MTs, leading to tau self-assembly into paired helical filaments (PHF) ([@B76]).

Phosphorylation of tau detaches it from MTs to allow the intracellular transportation of subcellular organelles such as mitochondria and lysosomes from the nerve terminals to the cells\' soma through secretory vesicles ([@B134]). Hyperphosphorylation of tau sequesters the normal tau in which it may excessively impair tau binding and destabilize MTs, thus, impairing the axonal transport causing neurodegeneration through synaptic starvation, neurite outgrowth, and neuronal death ([@B112]). Hyperphosphorylated tau tends to misfold and forms PHF which eventually aggregates to form NFTs as a defense mechanism in the cell soma ([@B58]).

In contrast to Aβ pathology, which causes hyperactivity of neurons, tau silences the neurons ([@B19]). This provokes the question on how the coexistence of Aβ and tau pathologies causes neurodegeneration in AD. From the fully eradicated neuronal hyperactivity and drastic decline of cortical activity in rats with both Aβ and tau pathologies, it can be concluded that deposition of Aβ plaques may be the triggering factor that sparks other AD etiologies, but tau pathology is the one dominating the aftermath effects of this dual proteinopathies in AD. It is tau pathology that determines the cognitive status in AD compared to Aβ pathology, which is another solid reason for the constant failures of Aβ drugs. The combination of anti-amyloid and anti-tau is crucial, as suppressing gene expression of tau is less effective in restoring the neuronal impairments in the presence of Aβ plaques ([@B39]).

Current Drugs Targeting Aβ - Failures {#s4}
=====================================

According to the updated AD drug development pipeline in 2018, although more than 50% of drugs in Phase III trials are targeting Aβ, there is still a steep 40% decline from year 2017 to 2018 in anti-Aβ drugs in Phase I and II trials, which manifests the shift in AD research following the repetitive failures of anti-Aβ drugs ([@B116]) ([**Table 2**](#T2){ref-type="table"}). Reducing the generation of Aβ~42~, inhibiting the aggregation of Aβ plaques, or increasing the rate of Aβ clearance from the cerebrospinal fluid (CSF) and brain are the common approaches of anti-Aβ drugs ([@B143]). At present, the complexity of AD\'s pathogenesis is vaguely understood, which may involve numerous other proteins beside Aβ and various biological pathways ([@B41]). This multifactorial AD pathogenesis is most probably the main reason for the repetitive failures of anti-amyloid drugs because a single target treatment may not be able to cater for all the altered pathways involved in the neurodegenerative events ([@B147]).

###### 

Failed clinical trials of anti-Aβ drugs for the treatments of Alzheimer\'s disease.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name           Therapy Type                  Clinical Trials   Cohort                 Reason of failure                                                                                References
  -------------- ----------------------------- ----------------- ---------------------- ------------------------------------------------------------------------------------------------ ------------
  Solanezumab    IgG1 humanized anti-Aβ mAbs   III               Mild-to-moderate AD    Lack of efficacy                                                                                 ([@B72])

  Bapineurumab   IgG1 humanized anti-Aβ mAbs   III               Mild-to-moderate AD    Lack of efficacy                                                                                 ([@B141])\
                                                                                                                                                                                         ([@B85])

  Crenezumab     IgG1 humanized anti-Aβ mAbs   II                Mild-to-moderate AD    Lack of efficacy,\                                                                               ([@B33])
                                                                                        Did not meet primary and secondary endpoint.                                                     

  Gantenerumab   IgG1 humanized anti-Aβ mAbs   III               Prodromal AD           Halted due to futility, no significant differences observed in primary and secondary endpoint.   ([@B126])

  Aducanumab     IgG1 humanized anti-Aβ mAbs   III               Mild-to-moderate AD    Lack of efficacy                                                                                 ([@B147])\
                                                                                                                                                                                         ([@B65])\
                                                                                                                                                                                         ([@B149])

  Tramiprosate   Aβ aggregation inhibitor      II                                       Lack of efficacy                                                                                 ([@B146])\
                                                                                                                                                                                         ([@B140])\
                                                                                                                                                                                         ([@B88])\
                                                                                                                                                                                         ([@B107])

  Semagacestat   γ-secretase inhibitor         III                                      Lack of efficacy,\                                                                               ([@B42])\
                                                                                        Worsens cognition function at higher doses,\                                                     ([@B70])
                                                                                        High incidence of skin cancer and infections                                                     

  Verubecestat   BACE1 inhibitor               III               Mild-to-moderate AD\   Lack of efficacy,\                                                                               ([@B46])\
                                                                 Prodormal AD           Adverse events:\                                                                                 ([@B83])
                                                                                        Occurrence of rash\                                                                              
                                                                                        Changes in hair color\                                                                           
                                                                                        Tend to have more falls and injuries\                                                            
                                                                                        Weight loss\                                                                                     
                                                                                        Sleep disturbance\                                                                               
                                                                                        Suicidal ideation                                                                                

  Lanabecestat   BACE1 inhibitor               III               Early AD\              Unlikely to meet primary endpoint, stopped for futility                                          ([@B48])\
                                                                 Mild-to-moderate AD                                                                                                     ([@B25])\
                                                                                                                                                                                         ([@B47])

  Atabecestat    BACE1 inhibitor               II/III            Early AD               Adverse events:\                                                                                 ([@B161])\
                                                                                        Elevation of liver enzymes                                                                       ([@B159])\
                                                                                                                                                                                         ([@B77])

  Avagacestat    γ-secretase inhibitor         II                Prodromal AD           Lack of efficacy\                                                                                ([@B31])
                                                                                        Adverse events:\                                                                                 
                                                                                        Weight loss\                                                                                     
                                                                                        Glycosuria                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Initially, these anti-Aβ agents show potential curative effects through effective Aβ clearance in CSF and the brain during the early stage of drug development. However, the Aβ level in mild-to-moderate AD patients or even prodromal AD patients may have reached the threshold of irreversible neurotoxicity, which is the main reason for the failure of many anti-Aβ drugs once proceeded to phase III trials ([@B40]). This is probably due to lack of AD biomarkers in the past to ensure early detection and recruitment of potential AD patients for clinical trials ([@B54]). Plus, Aβ plaques accumulate at a slow rate which may provide a large time window for a potential intervention that could either enhance the clearance or hinder the accumulation of Aβ insoluble proteins before brain atrophy and memory impairment commences ([@B166]). According to PET images taken by Vlassenko and colleagues, significant changes in CSF Aβ level and Aβ deposition in the brain of AD patients were reported, respectively 25 and 15 years prior to the clinical representation of AD symptoms ([@B167]). This finding suggested an optimal time for early intervention of AD; hence, early treatment can be given to the presymptomatic AD patients who should have been recruited for clinical trials rather than symptomatic AD patients. This is mainly because symptomatic AD patients usually have irreversible synaptic loss and neuronal deaths. Therefore, better recruitment of patients with earlier stage of neurodegeneration and more consistent pathology underlying their AD to participate in clinical trials may generate more beneficial clinical outcomes ([@B18]).

The targeted protein to minimize the generation of Aβ42 is β-secretase 1 (BACE1), which is involved in the first proteolytic cleavage of the APP protein and also γ-secretase which plays a role in the second cleavage in order to produce the Aβ42 protein.Verubecestat, a BACE1 inhibitor, was discontinued from the phase III trial due to its lack of efficacy and inability to establish a positive risk/benefit ratio towards mild-to-moderate and prodromal AD patients, although significant reduction of Aβ in the patients\' CSF and brains were achieved during the trial ([@B46]). This finding emphasized that solely targeting amyloid may not be an appropriate strategy in treating AD. Lanabecestat is a selective BACE1 inhibitor with satisfying blood-brain barrier (BBB) penetration, high potency and permeability, and slow off-rate that is critical for its efficacy ([@B47]). However, lanabecestat was discontinued from the trials due to its unlikeliness to meet the primary end points in mild-to-moderate and prodromal AD patients based on a recommendation from the data monitoring committee ([@B131]). Meanwhile, a phase II/III trial of a non-selective BACE1, atabecestat, was halted as the benefit/risk ratio was no longer favorable due to chronic elevations of liver enzymes observed during the trial ([@B159]).

The clinical trial of semagacestat was rushed without a strong foundation of knowledge on the compound\'s physiological, structural, and functional properties ([@B35]). It was even more perplexing when the trial of semagacestat continued to the next phase without any significant results from the previous trial and was terminated before the completion of phase III trial. The drug was not even as effective as the placebo, aggravated cognitive deterioration at higher doses, and demonstrated high incidence of skin cancer and infections in the study group ([@B42]). The drug\'s adverse effects may potentially be linked to the altered Notch signaling pathway, where Notch was one of the alternate substrates for γ-secretase, important for cell differentiation. Blocking γ-secretase through semagacestat may have blocked the differentiation of cells vital for the immune system, pigmentation, and gastrointestinal functions such as B and T lymphocytes, melanocyte stem cells, and gastrointestinal epithelial cells ([@B70]). The loss of Notch signaling by semagacestat may trigger mutations responsible for the development of skin cancer in patients\' groups receiving semagacestat ([@B121]).

Apart from that, tramiprosate was an anti-glycosaminoglycan compound that targeted the inhibition of Aβ aggregation studied until the phase II trial ([@B54]). Aβ binds with glycosaminoglycan on the cell surface for cellular uptake and internalization depending on the electrostatic interaction between the positively charged Aβ and negatively charged sulfate residue on the glycoaminoglycan ([@B154]). Tramiprosate was also withdrawn from the trial due to a lack of consistent cognitive improvement as measured in Alzheimer\'s Disease Assessment Scale-cognitive subscale (ADAS-Cog) ([@B3]). Nevertheless, tramiprosate was found to have higher efficacy to apolipoprotein E4 homozygotes in AD patients. Therefore, a thorough molecular analysis elucidated the mechanism of action of tramiprosate in aggregate Aβ~42~ that may be advantageous for further development of tramiprosate as an AD therapeutic regimen ([@B140]). Concisely, tramiprosate prevents the misfolding of self-assembled Aβ~42~ monomers by enveloping them, thereby hindering the aggregation of neurotoxic Aβ~42~ plaques ([@B88]).

Besides, extensive development of Aβ humanized IgGI monoclonal antibodies agents, such as solanezumab and bapineuzumab, that targeted the central epitopes of soluble Aβ monomers and the N-terminus of Aβ~42~ were also halted due to a lack of efficacy in mild-to-moderate AD patients ([@B72]; [@B23]). After repetitive failures in phase III clinical trials in mild-to-moderate AD patients, EXPEDITION 1, EXPEDITION 2 and EXPEDITION 3, solanezumab are currently being tested in asymptomatic and mildly symptomatic patients with biomarker evidence of Aβ plaques deposition in brains as a preventive strategy towards AD ([@B176]). A combined therapy of solanezumab and gantenerumab was also terminated due to their lack of clinical advantages and apparent side effects when combined with BACE1 inhibitor ([@B34]). The combination therapy was initiated to enhance the immune response towards Aβ plaques, hence, promoting Aβ clearance while BACE1 inhibits the generation of new Aβ ([@B54]). Nonetheless, there are two emerging anti-Aβ oligomers monoclonal antibodies with promising efficacy, aducanumab and BAN2401, that bind to insoluble fibrils and soluble Aβ protofibrils, thus, relieving the brains\' Aβ burden with positive impact on cognition ([@B131]). Aducanumab is an Aβ-targeting monoclonal antibody that is currently showing significant dose-dependent reduction of Aβ plaques\' size ([@B65]). Besides binding to both forms of Aβ, soluble oligomers and insoluble fibrils, aducanumab also alleviates calcium dyshomeostasis in affected neurons, since neuronal calcium was found altered in AD brains ([@B57]). Further studies should investigate whether the alleviation of elevated intracellular calcium by aducanumab plays a role in restoring the cognitive functions in AD. In a phase III trial, aducanumab failed to slow down cognitive deterioration in mild-to-moderate patients due to reasons such as the patients were irreversibly symptomatic, targeting Aβ was not sufficient as it may have already caused irreversible synapse and microglia toxicity, and multifactorial AD may require combination therapy ([@B147]).

BAN2401 is a humanized monoclonal antibody with encouraging therapeutic effects in treating AD. The drug is highly selective to Aβ protofibrils and recedes the formation of Aβ plaques, causing a 30% delay to cognitive impairment in mild-to-moderate AD patients within 18 months and a 47% delay by the highest dose in a phase II trial ([@B157]). However, future studies should explore the potential of this drug in a larger group ([@B111]; [@B131]).

Passive immunization is the most predominant therapeutic approach in targeting Aβ where exogenous monoclonal antibodies (mAbs) are administered to the patients. However, this approach has been weighted with repetitive failures that subsequently theorized several augmentations for the anti-Aβ mAbs development ([@B133]). Firstly, mAbs targeting the N-terminus of Aβ are highly potent in suppressing the aggregation of Aβ and disaggregating the pre-existing Aβ fibrils ([@B163]). Next, better penetration through the BBB and higher doses of mAbs may be tested in the future since mAbs have astonishing safety profiles. Finally, recruiting preclinical AD patients for the prevention of AD clinical trials is one of the initiatives taken to maximize the benefits of anti-Aβ mAbs in treating AD at an early stage ([@B66]).

Emerging Treatments: Neuroinflammation {#s5}
======================================

Recently, the drive for new therapeutic strategies has focused on neuroinflammation interceded by microglia and astrocytes in AD pathogenesis, rather than the accustomed AD hypotheses such as Aβ and tau pathologies. This has resulted in extensive investigations of anti-inflammatory and antioxidant agents ([@B69]). In a healthy brain, microglia provide protection against exogenous insult, while astrocytes furnish nutritional and structural support for neurons ([@B164]). At the early stages of AD, excessive deposition of extracellular Aβ plaques and continuous activation of glial cells cause the release of inflammatory cytokines such as interleukin-1α (IL-1α), tumor necrosis factor-α (TNF-α), and complement protein (C1q) ([**Figure 1**](#f1){ref-type="fig"}). The cytokines also increase astrocytes\' expression of insulin-degrading enzyme (IDE) for Aβ degradation and signal for neuronal apoptosis ([@B153]). NFκB signaling cascades enhanced in glial cells of AD brain to produce various inflammatory and immune proteins, including compliment component 3 (C3) that initiates neural destruction through complement-mediated synapse pruning when it binds to C3a receptors on a neuron ([@B9]).

![Neuroinflammation in Alzheimer\'s disease. Aβ plaques, NFTs and oxidative stress dysregulate various signaling cascades, causing neuroinflammation, and eventually neurodegeneration. Multiple novel pharmacotherapies ameliorate AD by normalizing the dysregulated signaling pathways in AD. IDE, insulin-degrading enzyme; Aβ, amyloid βeta; IL-1α, interleukin 1α; TNF-α, tumour necrosis factor-α; C3, complement component 3; C1q, complement protein 1q; TREM2, triggering receptor expressed on myeloid cells 2; ITAM, immunoreceptor tyrosine-based activation motif; SYK, spleen tyrosine kinase; P, phosphate; PI3K, phosphatidylinositol 3-kinase; NFκB, nuclear factor kappa β; RIPK1, receptor-interacting serine/threonine-protein kinase 1; *Cst7*, cystatin F gene; RTK, receptor tyrosine kinase; PDK1, phosphoinositide-dependent kinase 1; mTOR, mammalian Target of Rapamycin; Akt, protein kinase B; GSK-3β, glycogen synthase kinase 3β; TSC, tuberous sclerosis complex; AMP, adenosine monophosphate; AMPK, AMP-activated protein kinase; SIRT1, silent information regulator type 1; BACE1, β-secretase 1; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; CREB, cAMP response element binding protein; NMDAR, NMDA receptor; Ca²⁺/Calmodulin-dependent protein kinase II (CAMKII); LIMK1, LIM kinase 1; BDNF, brain-derived neurotrophic factor. Asterisk (\*) in the diagram indicates uncertain changes of activity in AD.](fphar-11-00261-g001){#f1}

Constant production of inflammatory cytokines by microglia leads to neuroinflammation and synaptic loss. Neuroinflammation suppresses the phagocytosis of Aβ plaques which may aggravate neurodegeneration ([@B30]). Despite the undefined mechanism of rilapladib, it is presumed that rilapladib reduces neuroinflammation through the reduction of proinflammatory cytokines and restoration of BBB integrity ([@B106]; [@B75]).

Microglia are activated into disease-associated microglia (DAM) through triggering receptors expressed on myeloid cells 2 (TREM2) independent and dependent pathways during the microglia-Aβ plaques interaction, which facilitate Aβ plaques phagocytosis and suppresses overproduction of inflammatory cytokines ([@B84]). Activation of TREM2 leads to the phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM) that causes the spleen tyrosine kinase (SYK) to dock within the receptor complex and activates the phosphatidylinositol 3-kinase (PI3K) cascades ([@B182]). The initial response following the activation of PI3K pathway was to produce pro-inflammatory cytokines as a neuroprotective feedback ([@B29]). Several studies reported that mutations of TREM2 in AD reduced the phagocytic capacity of DAM, disrupted the downstream PI3K pathway, and impaired suppression of pro-inflammatory cytokines released by the glial cells ([@B78]; [@B2]). Meanwhile, overexpression of TREM2 ameliorated neuroinflammation by inhibiting the pro-inflammatory responses initiated by microglia ([@B137]).

In addition, restoring the microglia function in Aβ clearance may open new doors for the development of AD treatments through inhibiting receptor-interacting serine/threonine protein kinase 1 (RIPK1) that are highly expressed in microglia of AD brains ([@B117]). Inhibition of RIPK1 reduces the overexpression of *Cst7* that encodes for cystatin F, an endosomal/lysosomal cathepsin inhibitor, which reduces the phagocytic capacity of primary immune cells ([@B123]). Therefore, RIPK1 inhibitor is suggested to encounter neuroinflammation caused by inflamed microglia that disrupts the phagocytosis of toxic dead cells by reducing the expression of *Cst 7* and escalating Aβ plaques clearance.

Overstimulation of glutamate receptors leads to the progression of many CNS-related complications ([@B91]; [@B92]). Aβ plaques cause glutamatergic hyperexcitation through continuous stimulation of NMDAr that results in its desensitization and an increase in Ca^2+^ influx ([@B172]). NSAIDs such as diclofenac and rofecoxib were said to be a potential strategy in combating neuroinflammation by regulating Ca^2+^ homeostasis, tau phosphorylation, axonal growth, and astrocyte motility through Rho-GTPases pathway ([@B90]). The binding of Ca^2+^ with calmodulin forms Ca^2+^/Calmodulin complex, which subsequently activates Ca²⁺/Calmodulin-dependent protein kinase II (CAMKII) and Rho-GTPases pathway, which is important for in spine morphogenesis during the induction of long-term potentiation (LTP) ([@B105]). LIM kinase 1 (LIMK1), a downstream kinase in Rho-GTPases pathway, phosphorylates and inhibits cofilin, a protein involved in the depolymerization of f-actin ([@B49]). Aβ was reported to disrupt the Rho-GTPases pathway, which regulates the dynamic of polymerization and depolymerization of f-actin to maintain the neurons\' morphology ([@B51]). Meanwhile, ibuprofen was shown to phosphorylate cofilin at S3 to inhibit cofilin, thus, preventing the depolymerization of f-actin and impairment of synaptic plasticity. Besides, NSAIDs also suppress the microglial activation and lessen the accumulation of activated microglia ([@B122]). But, NSAIDs tend to cause toxicity due to its non-selective activity. In addition, rofecoxib, a specific cyclooxygenase-2 (COX-2) inhibitor was studied in AD as COX-2 mRNAs were upregulated in AD brains ([@B170]). Inhibiting COX-2 may also hinder the decline of LTP provoked by the deposition of Aβ in the hippocampus ([@B37]).

Besides, phenolic compounds with antioxidant properties such as oleuropein and epigallocatechin gallate (EGCG) are also of interest for early intervention in AD management ([@B80]). This is mainly because a significant deficiency in brain antioxidant levels was identified as the oxidative stress marker in AD ([@B151]). For instance, EGCG was said to suppress the Aβ plaque-induced upregulation of proinflammatory cytokines in microglia, and also upregulate the expression of endogenous antioxidants such as nuclear arythroid-2 related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). Hence, EGCG elicits a protective effect against oxidative stress and neuroinflammation ([@B28]).

Novel Pharmacology: Molecular Targets {#s6}
=====================================

Development of novel AD pharmacotherapy is becoming profoundly important as the complexity of AD pathogenesis becomes better understood in recent times, resulting in the exploration of multitude targets in AD therapeutic strategies ([**Table 3**](#T3){ref-type="table"}). The pipeline of AD treatments is augmented with compounds that either modify the underlying AD pathophysiology, target several molecular targets synergistically, or repurposed as an anti-Alzheimer\'s drug ([@B6]).

###### 

Novel clinical trials for Alzheimer\'s disease.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                                                    Mechanism                                                                                                                                                Clinical trials                                                                                                                                                                                                                                                                References
  ------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------
  Masatinib\                                              GSK-3β Inhibitor\                                                                                                                                        Phase II/III trial on mild-to-moderate AD patients\                                                                                                                                                                                                                            ([@B129])\
  (AB1010)                                                Tyrosine kinase inhibitor target mast cells and macrophages.                                                                                             Escalated dose: 4.5 mg/kg/day b.i.d., escalate to 6 mg/kg/day after 3 months\' treatment\                                                                                                                                                                                      ([@B1])\
                                                                                                                                                                                                                   Fixed dose: 4.5 mg/kg/day b.i.d. and 3.0 mg/kg/day b.i.d.\                                                                                                                                                                                                                     ([@B52])
                                                                                                                                                                                                                   Primary endpoint: ADCS-ADL that indicates self-care and activities of daily livingADAS-Cog that measure the effect on cognition and memorySecondary endpoint: MMSECIBIC-plus                                                                                                   

  Methylene blue (MB)\                                    Inhibit the formation of tau oligomers                                                                                                                   Phase II clinical trial on healthy aging, mild cognitive impairment (MCI), and mild AD patients\                                                                                                                                                                               ([@B34])\
  NCT02380573                                                                                                                                                                                                      Primary endpoint: Working memory taskWorking memory task responseEpisodic memory taskEpisodic memory responseSustained attention taskNeurological battery composite scoreSecondary endpoint: Cerebral blood flow measures                                                      ([@B152])\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ([@B60])

  Metformin\                                              Biguanide class medication\                                                                                                                              Phase II clinical trial on MCI and early AD patients\                                                                                                                                                                                                                          ([@B127])\
  NCT01965756                                             Decrease insulin level that affect the clearance of Aβ in brain\                                                                                         Metformin \> Placebo\                                                                                                                                                                                                                                                          ([@B104])\
                                                          Decrease advanced glycation end products and inflammation in AD                                                                                          oral metformin for 8 weeks (500 mg q.d. for 1 week, increased dose by 500 mg per week until a maximum dose of 2000 mg per day), followed by 8 weeks of placebo\                                                                                                                ([@B21])\
                                                                                                                                                                                                                   Placebo \> Metformin\                                                                                                                                                                                                                                                          ([@B174])
                                                                                                                                                                                                                   After 8 weeks of placebo, oral metformin for 8 weeks (500 mg q.d. for 1 week, increased dose by 500 mg per week until a maximum dose of 2000 mg per day)\                                                                                                                      
                                                                                                                                                                                                                   Primary endpoint: Word List Memory Total (ADAS-cog)Secondary endpoint: Trails-B                                                                                                                                                                                                

  RPEL                                                    Improve inhibition of AChE, reduce Aβ aggregation and reduce phosphorylation of tau                                                                      *In vivo* and *in vitro* studies                                                                                                                                                                                                                                               ([@B148])

  Tideglusib\                                             Thiadiazolidinone acts as an GSK-3β inhibitor, reduce tau phosphorylation and prevent neurons apoptosis.\                                                Phase II clinical trial on mild-to-moderate AD patients for 26 weeks\                                                                                                                                                                                                          ([@B38])\
  NCT01350362                                             Anti-inflammatory                                                                                                                                        Oral tideglusib 1000 mg q.d. Oral tideglusib 1000 mg.q.o.d. once every other day\                                                                                                                                                                                              ([@B169])
                                                                                                                                                                                                                   Oral tideglusib 500 mg q.d. Placebo q.d.\                                                                                                                                                                                                                                      
                                                                                                                                                                                                                   Primary endpoint: ADAS-Cog+                                                                                                                                                                                                                                                    

  Elenbecestat\                                           BACE1 inhibitor that inhibit BACE1 involved in amyloid precursor protein (APP) proteolytic cleavage during the formation of Aβ                           Phase II clinical trial on prodromal AD and mild-to-moderate AD patients\                                                                                                                                                                                                      ([@B54])\
  NCT03036280                                                                                                                                                                                                      Phase III clinical trial on early AD patients\                                                                                                                                                                                                                                 ([@B130])
                                                                                                                                                                                                                   Dosage:\                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                   50 mg q.d in the morning\                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                   MissionAD1 and MissionAD2 - Phase III trial on early AD with positive biomarkers for brain amyloid pathology.\                                                                                                                                                                 
                                                                                                                                                                                                                   Primary endpoint: CDR-SB\                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                   Contact dermatitis, upper respiratory infection, headache, diarrhea, fall and dermatitis.                                                                                                                                                                                      

  BAN2401\                                                IgG1 humanized anti-Aβ mAbs that binds selectively to Aβ protofibrils.                                                                                   Phase III clinical trial on early AD patients\                                                                                                                                                                                                                                 ([@B11])\
  NCT03887455                                                                                                                                                                                                      Dosage: 10 mg/kg i.v. BAN2401 biweekly\                                                                                                                                                                                                                                        ([@B157])\
                                                                                                                                                                                                                   Primary endpoint: Change on CDR-SB from baselineNumber of participants with treatment-emergent adverse events (TEAEs)Secondary endpoint: Change on amyloid Positron Emission Tomography (PET) from baselineChange on ADCOMS from baselineChange on ADAS-cog 14 from baseline   ([@B99])

  CT1812\                                                 Lipophilic isoindoline that bind allosterically to sigma-2 receptor complex and destabilize the Aβ oligomers binding at synapses\' neuronal receptors.   Phase I clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                        ([@B63])\
  NCT03522129                                                                                                                                                                                                      Dosage: 90 mg, 280 mg, 560 mg CT1812\                                                                                                                                                                                                                                          ([@B24])
                                                                                                                                                                                                                   Primary endpoint: Displacement of Aβ oligomers into CSF                                                                                                                                                                                                                        

  Nilotinib\                                              Inhibit brain Aβ,\                                                                                                                                       Phase II clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                       ([@B175])\
  NCT02947893                                             Decrease Aβ and pTau\                                                                                                                                    Dosage: oral 150 mg/capsule nilotinib q.d, 2 capsules after 6 months of 1 capsule\                                                                                                                                                                                             ([@B128])\
                                                          Modulate brain and peripheral immune profiles\                                                                                                           Primary endpoint: Number of participants with adverse events/abnormal laboratory values                                                                                                                                                                                        ([@B120])
                                                          Reverse cognitive decline in AD                                                                                                                                                                                                                                                                                                                                                                                                         

  Acitretin\                                              α-secretase enhancer/amyloid aggregation inhibitor, Retinoic acid receptor agonist                                                                       Phase II clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                       ([@B43])\
  NCT01078168                                                                                                                                                                                                      Dosage: oral 30 mg q.d.\                                                                                                                                                                                                                                                       ([@B56])
                                                                                                                                                                                                                   Primary endpoint: Difference in soluble alpha-cleaved APP in CSF                                                                                                                                                                                                               

  Pinitol(NIC5-15)\                                       α-secretase inhibitor that is Notch sparing                                                                                                              Phase II clinical trial on AD patients\                                                                                                                                                                                                                                        ([@B5])\
  NCT00470418                                                                                                                                                                                                      Primary endpoint: Number of participants with adverse events                                                                                                                                                                                                                   ([@B93])

  Bryostatin\                                             α-secretase enhancer, PKC modulator -- immunomodulatory effect, increase cognitive ability                                                               Phase II clinical trial on moderately severe-to-severe AD patients\                                                                                                                                                                                                            ([@B50])
  NCT02431468                                                                                                                                                                                                      Dosage: 20 & 40 μg Bryostatin, i.v.\                                                                                                                                                                                                                                           
                                                                                                                                                                                                                   Primary endpoint: Number of participants with TEAE and SAEChange in Severe Impairment Battery (SIB) in the Full Analysis Set (FAS)Secondary endpoint: SIBADCS-ADL-SEVMMSE-2NPICGI-I                                                                                            

  Bexarotene\                                             Retinoid X receptors (RXR) agonist to reduce Aβ in the brain                                                                                             Phase II clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                       ([@B32])
  NCT01782742                                                                                                                                                                                                      Dosage: 75 mg of bexarotene b.i.d., 150 mg after 1 week\                                                                                                                                                                                                                       
                                                                                                                                                                                                                   Primary endpoint: Change in brain amyloid burden measured by standard uptake unit regional (SUVr) according to genotypes involved in this trialSecondary endpoint: MMSEADAS-cogCDRNPIADCS-ADLSerum Aβ~1-42~ levelRatio of Aβ~42~ to Aβ~40~ in non-ApoE4 carriers               

  ELND005 (formerly known as AZD-103), scyllo-inositol\   Inhibit the build-up of amyloid protein in AD brains                                                                                                     Phase II clinical trial on moderate-to-severe AD patients\                                                                                                                                                                                                                     ([@B96])
  NCT01735630                                                                                                                                                                                                      Dosage: ELND005 tablets, b.i.d. for 12 weeks\                                                                                                                                                                                                                                  
                                                                                                                                                                                                                   Primary endpoint: Change in NPI-C combined agitation and aggressionSecondary endpoint: ADCS-CGICNPIMMSEADCS-ADL                                                                                                                                                                

  ABT-354\                                                5-HT~6~ antagonist regulate the release of acetylcholine, glutamate and noradrenaline in the forebrain region.                                           Phase I clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                        ([@B51])\
  NCT01908010                                                                                                                                                                                                      Primary endpoint:\                                                                                                                                                                                                                                                             ([@B94])
                                                                                                                                                                                                                   Vital signsECGNeurological examLaboratory tests (hematology, chemistry, urinalysis)Number of participants with adverse eventsC-SSRSSecondary endpointPharmacokinetic parameters                                                                                                

  CNP520\                                                 BACE1 Inhibitor                                                                                                                                          Generation Study 2 -- Phase II/III trial on homozygotes *APOE ϵ4* and heterozygotes *APOE ϵ4* carriers with elevated brain amyloid.\                                                                                                                                           ([@B103])\
  NCT03131453                                                                                                                                                                                                      Dosage: p.o. 15 mg/day or 50 mg/day CNP520\                                                                                                                                                                                                                                    ([@B130])\
                                                                                                                                                                                                                   Primary endpoint: diagnosis of MCIAPCC test score.                                                                                                                                                                                                                             ([@B16])

  Crenezumab\                                             Amyloid monoclonal antibodies                                                                                                                            Phase III clinical trial on prodromal to lid AD patients\                                                                                                                                                                                                                      ([@B33])
  NCT02670083                                                                                                                                                                                                      Dosage: i.v. crenezumab q4w for 100 weeks\                                                                                                                                                                                                                                     
                                                                                                                                                                                                                   Primary endpoint: Change in CDR-SB                                                                                                                                                                                                                                             

  Rilapladib\                                             Lipoprotein-associated phospholipase A~2~ (Lp-PLA~2~) inhibitor that suppress neuroinflammation                                                          Phase IIa clinical trial on AD patients\                                                                                                                                                                                                                                       ([@B106])
  NCT01428453                                                                                                                                                                                                      Dosage: 250 mg rilapladib\                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                   Primary endpoint: Change in Aβ~42~ and Aβ~40~ level in CSFRatio of Aβ~42~/Aβ~40~ in CSFTau and p-tau in CSFWorking memory/executive function (WM/EF) composite score                                                                                                           

  Edonerpic Maleate\                                      Activate sigma-1 receptor and regulate the microglial function.                                                                                          Phase II clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                       ([@B145])
  (T-817MA)\                                                                                                                                                                                                       Dosage: 224 mg of T-817MA q.d., 448 mg after 4 weeks\                                                                                                                                                                                                                          
  NCT02079909                                                                                                                                                                                                      Primary endpoint: Change in ADAS-cogCGICSecondary endpoint: ADCS-ADL                                                                                                                                                                                                           

  Carvedilol\                                             Non-selective B-adrenergic receptor blocker that indirectly reduce neurons\' apoptosis.                                                                  Phase IV clinical trial on AD patients\                                                                                                                                                                                                                                        ([@B98])
  NCT01354444                                                                                                                                                                                                      Dosage: 25 mg of carvediol daily\                                                                                                                                                                                                                                              
                                                                                                                                                                                                                   Primary endpoint: Hopkins Verball Learning Test (HVLT)Secondary endpoint: Aβ oligomers level in CSF                                                                                                                                                                            

  Intepirdine (RVT-101)\                                  5-HT~6~ antagonist                                                                                                                                       Phase III clinical trial on AD patients\                                                                                                                                                                                                                                       ([@B100])\
  NCT02585934                                                                                                                                                                                                      Dosage: 35 mg of oral RVT-101 q.d.\                                                                                                                                                                                                                                            ([@B101])\
                                                                                                                                                                                                                   Primary endpoint: Change in ADAS-cog 11ADCS-ADLSecondary endpoint: CIBIC+Dependence Scale (DS)Neuropsychiatric Inventory (NPI)ADAS-cog 13Plasma concentration of RVT-101                                                                                                       ([@B183])

  Vanutide Cridificar (ACC-001)\                          Vaccine that produce Aβ-directed B-cell response.                                                                                                        Phase II clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                       ([@B132])
  NCT00479557                                                                                                                                                                                                      Dosage: 3, 10, 30 μg IM on day 1, month 1, 3,6, and 12\                                                                                                                                                                                                                        
                                                                                                                                                                                                                   Primary endpoint: Percentage of participants with treatment-emergent adverse events (TEAEs) or serious adverse events (SAE)Secondary endpoint: Geometric mean titers (GMTs) of Anti-Aβ immunoglobulin (IgG) using Enzyme-linked Immunosorbent Assay (ELISA)                    

  Resveratrol\                                            SIRT1 potent activator acts as anti-inflammatory                                                                                                         Phase II clinical trial on mild-to-moderate AD patients\                                                                                                                                                                                                                       ([@B44])\
  NCT01504854                                                                                                                                                                                                      Dosage: 500 mg oral resveratrol q.d.\                                                                                                                                                                                                                                          ([@B115])\
                                                                                                                                                                                                                   Primary endpoint: Number of adverse eventsChange from baseline on volumetric magnetic resonance imaging (MRI)Secondary endpoint:ADCS-ADLCSF Aβ level                                                                                                                           ([@B162])
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Other potential treatments for AD include those based on the inhibition of glycogen synthase kinase-3β (GSK-3β) and mammalian target of rapamycin (mTOR) to attenuate neuroinflammation by increasing Aβ clearance and decreasing tau phosphorylation ([@B113]). Normally, extracellular ligands bind to a receptor tyrosine kinase (RTKs), which activate PI3K signaling cascades and lead to the activation of PDK-1 and Akt. PDK1 also indirectly activates the mTORC2 complex which activates Akt through the phosphorylation of the kinase at S473 and S450. Active Akt phosphorylates and activates tuberous sclerosis complex (TSC) 1 and 2, a negative regulator of mTORC1 ([@B71]). mTOR inhibition activates the ubiquitin proteasome system and autophagy. In AD brain, where PI3K/Akt signaling pathway is downregulated due to Aβ plaques-induced neurotoxicity, Akt is suppressed and mTORC1 activity is increased, which disrupts cell autophagy, leading to neuroinflammation ([@B150]). Wang and colleagues reported rapamycin\'s (mTORC1 inhibitor) ability to inhibit elevated activation of mTORC1 and pro-inflammatory cytokines in the hippocampus of AD rats ([@B171]). Suppressed Akt also promotes activation of GSK-3β to cause hyperphosphorylation of tau that aggregates to form NFTs once detached from the microtubules. The loss of microtubules\' integrity induces neuroinflammation and increases the risk of neuronal death ([@B108]).

Methylene blue (MB) is one of the anti-tau disease modifying agents (DMTs) that combats tau pathology through two molecular targets: GSK-3β and tau aggregation ([@B58]). Hyperphosphorylation of tau is associated with the loss of counterbalance between the kinases and phosphatases involved in tau phosphorylation, especially if the phosphorylation takes place at the sites of kinases as this family of enzymes regulate most of the protein function ([@B134]). Kinases involved in tau phosphorylation are mitogen-activated protein kinases (MAPKs), cyclin-dependent kinases (Cdks), GSK-3β, and protein kinase A (PKA) ([@B86]; [@B97]).

Initially, MB was well-known for its inhibiting activity on tau aggregation in AD clinical trials ([@B64]). In spite of the advance in knowledge on tau pathology, partial inhibition on tau aggregation by MB is not adequate to halt AD as the underlying event that causes tau-mediated neurotoxicity is the binding of granular tau oligomers during NFT formation ([@B152]).

Binding of Aβ plaques or glutamate to synaptic receptors can initiate the production of cyclic adenosine monophosphate (cAMP) from adenylyl cyclase, activating the cAMP/PKA pathway. Under normal conditions, downstream cAMP/PKA pathway results in phosphorylation of transcription factors such as cAMP response element binding protein (CREB) at S133, which stimulates transcription and translation of genes involved in the formation of memory ([@B7]; [@B59]). However, the level of p-PKA was significantly decreased in the hippocampus of AD mice while neuroinflammation was found to be increased ([@B20]). Decreased PKA subsequently decreased the phosphorylated CREB in the rats\' hippocampus ([@B74]). High levels of BACE1 in AD brain inhibits adenylyl cyclase and impairs cAMP/PKA pathway, which interrupts the phosphorylation and eventually disrupts the transcription and translation of CREB-induced genes, leading to memory impairment in AD ([@B27]). CREB activation can restore memory impairment in AD as the CREB-induced genes, such as brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1, can enhance neuron morphological outgrowth and formation of long-term and short-term memories ([@B89]).

Metformin is a first-line medication for type 2 diabetes, which was repurposed for AD treatment as it exhibits anti-inflammatory properties and neuroprotective features against cognitive deterioration in AD ([@B127]). Metformin hinders the neuronal apoptosis and promotes neurogenesis in the hippocampus through the activation of the AMP-activated protein kinase (AMPK) pathways, which leads to the improvement of memory formation. AMPK can be phosphorylated by 3 key kinases, such as the liver kinase B1 (LKB1) complex at T172, due to increased cytoplasmic level of AMP, increased cytosolic Ca^2+^, and mitogen-activated protein kinase 7 (MAP3K7), also known as transforming growth factor beta-activated kinase 1 (TAK1) ([@B173]). AMPK also activates TSC1/2 complex that inhibits mTOR ([@B173]). Activity of AMPK was decreased in the hippocampus of AD rats at age 4-5 months, while the activity of mTOR increased, causing disrupted cell autophagy and exacerbated AD ([@B45]; [@B156]). Inhibition of mTOR by rapamycin restores normal cell autophagy and protein synthesis ([@B155]).

PKA was found to activate silent information regulator type 1 (SIRT1), a neuroprotective protein deacetylase that reduces tau acetylation and downregulates BACE1, hence, increasing degradation of tau and reducing Aβ production ([@B181]; [@B173]). Resveratrol, through activation of SIRT1, reverses the drastic decrease in hippocampal expression of SIRT1 in AD ([@B162]; [@B73]). Resveratrol was also found to reduce neuronal apoptosis and eventually restore cognitive impairment in AD ([@B160]).

Current DMTs target either Aβ pathology or tau pathology, which may be the reason for their lack of efficacy since both pathologies synergistically cause cognitive degeneration with the cholinergic deficit as a constant concern in AD. Multi target-directed ligand (MTDLs) is a novel approach to surmount the multifactorial AD pathogenesis ([@B61]). RPEL was synthesized through the combination of N, N\'-disubstituted piperazine anti-amyloid scaffold and tacrine, into one compound ([@B148]). It was found effective in preventing cognitive impairment as it minimizes the Aβ plaques formation and tau phosphorylation in AD mice without any adverse effect besides maintaining the inhibitory activity on AChE. This approach accelerates the development of potential treatment for AD by minimizing the cost and time since the individual therapeutic effects of each compound is generally known ([@B67]).

Conclusion {#s7}
==========

Despite decades of research, we are still encountering a lack of success in pharmacotherapy of AD, mostly due to the multifactorial etiologies of the disorder that can initiate neurodegeneration interdependently. At present, combination therapy targeting several factors simultaneously appears to be promising. Additionally, an increasing number of studies are also focusing on neuroprotection against neuroinflammation. The impact of neuroinflammation interceded by microglia and astrocytes in AD pathogenesis is of great interest as it opens new doors for novel therapeutic targets. In addition to pharmacotherapy, better prognosis through early detection of AD biomarkers or brain imaging will enable early intervention that could potentially prevent the deposition of Aβ plaques and manifestations of various irreversible symptoms of AD.
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